In addition, combinative treatment using a glutathione transferase (GSTP-1) inhibitor-derived RAPTA compound (RAPTA-EA1) and olaparib significantly suppressed the expression levels of BRCA1 protein in triple-negative BRCA1 wild-type breast cancer cells [53]. This evidence concerns the gene BRCA1 and breast cancer.